OphSourceHomeJournal CollectionOphSource ShopEvents
Journal Home
Search for

Volume 116, Issue 7, Pages 1243-1249 (July 2009)


View previous. 5 of 41 View next.

Meta-analysis of Medical Intervention for Normal Tension Glaucoma

Jin-Wei Cheng, MD, Ji-Ping Cai, MD, Rui-Li Wei, MDCorresponding Author Informationemail address

Received 12 August 2008; received in revised form 14 January 2009; accepted 23 January 2009. published online 18 May 2009.

Objective

To evaluate the intraocular pressure (IOP) reduction achieved by the most frequently prescribed antiglaucoma drugs in patients with normal tension glaucoma (NTG).

Design

Systematic review and meta-analysis.

Participants

Fifteen randomized clinical trials reported 25 arms for peak IOP reduction, 16 arms for trough IOP reduction, and 13 arms for diurnal curve IOP reduction.

Methods

Pertinent publications were identified through systematic searches of PubMed, EMBASE, and the Cochrane Controlled Trials Register. The patients had to be diagnosed as having NTG. Methodological quality was assessed by the Delphi list on a scale from 0 to 18. The pooled 1-month IOP-lowering effects were calculated using the 2-step DerSimonian and Laird estimate method of the random effects model.

Main Outcome Measures

Absolute and relative reductions in IOP from baseline for peak and trough moments.

Results

Quality scores of included studies were generally high, with a mean quality score of 12.7 (range, 9–16). Relative IOP reductions were peak, 15% (12%–18%), and trough, 18% (8%–27%) for timolol; peak, 14% (8%–19%), and trough, 12% (−7% to 31%) for dorzolamide; peak, 24% (17%–31%), and trough, 11% (7%–14%) for brimonidine; peak, 20% (17%–24%), and trough, 20% (18%–23%) for latanoprost; peak, 21% (16%–25%), and trough, 18% (14%–22%) for bimatoprost. The differences in absolute IOP reductions between prostaglandin analogues and timolol varied from 0.9 to 1.0 mmHg at peak and −0.1 to 0.2 mmHg at trough.

Conclusions

Latanoprost, bimatoprost, and timolol are the most effective IOP-lowering agents in patients with NTG.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Available online: May 17, 2009.

Department of Ophthalmology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

Corresponding Author InformationCorrespondence: Rui-Li Wei, MD, Department of Ophthalmology, Shanghai Changzheng Hospital, 415 Fengyang Road, Shanghai 200003, China

 Manuscript no. 2008-967.

 Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

PII: S0161-6420(09)00096-7

doi:10.1016/j.ophtha.2009.01.036


View previous. 5 of 41 View next.